Affordable Access

deepdyve-link
Publisher Website

Screening for clinically significant non-deletional alpha thalassaemia mutations by pyrosequencing.

Authors
  • Haywood, Anna
  • Dreau, Helene
  • Timbs, Adele
  • Schuh, Anna
  • Old, John
  • Henderson, Shirley
Type
Published Article
Journal
Annals of Hematology
Publisher
Springer-Verlag
Publication Date
Dec 01, 2010
Volume
89
Issue
12
Pages
1215–1221
Identifiers
DOI: 10.1007/s00277-010-1013-2
PMID: 20567827
Source
Medline
License
Unknown

Abstract

Non-deletional α(+)-thalassaemia is associated with a higher degree of morbidity and mortality than deletional forms of α(+)-thalassaemia. Screening for the common deletional forms of α-thalassaemia by Gap-PCR is widely practiced; however, the detection of non-deletional α-thalassaemia mutations is technically more labour-intensive and expensive, as it requires DNA sequencing. In addition, the presence of four very closely homologous alpha globin genes and the frequent co-existence of deletional forms of α-thalassaemia present another layer of complexity in the detection of these mutations. With growing evidence that non-deletional α-thalassaemia is relatively common in the UK, there is a demand for technologies which can quickly and accurately screen for these mutations. We describe a method utilising pyrosequencing for detecting the ten most common clinically significant non-deletional α-thalassaemia mutations in the UK. We tested 105 patients with non-deletional α-thalassaemia and found 100% concordance with known genotype as identified by Sanger sequencing. We found pyrosequencing to be simpler, more robust, quicker, and cheaper than conventional sequencing, making it a good choice for rapid and cost-effective diagnosis of patients with suspected non-deletional α-thalassaemia. The technique is also likely to help expedite prenatal diagnosis of pregnancies at risk of α-thalassaemia major.

Report this publication

Statistics

Seen <100 times